FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028662865> ?p ?o ?g. }

• W2028662865 endingPage "1330" @default.
• W2028662865 startingPage "1323" @default.
• W2028662865 abstract "Abstract BACKGROUND The primary objective of this study was to evaluate the biochemical effects of gefitinib on its target signal‐transduction pathways in patients with recurrent epithelial ovarian cancer (EOC). The secondary objectives included assessing clinical activity and toxicity and determining the association between biochemical and clinical outcomes. METHODS Twenty‐four heavily pretreated patients with EOC who had good end‐organ function and performance status and who had measurable disease received gefitinib 500 mg daily. Prospectively planned core‐needle tumor biopsies were obtained before treatment and after 4 weeks. Protein expression of total and phosphorylated (p) epidermal growth factor receptor (EGFR), protein kinase B (AKT), and extracellular regulated kinase (ERK) was quantified in microdissected tumor cells using tissue lysate array proteomics. RESULTS All tumor samples had detectable levels of EGFR and p‐EGFR. A decrease in the quantity of both EGFR and p‐EGFR was observed with gefitinib therapy in >50% of patients. This was not associated with clinical benefit, nor were responses observed. However, trends for increased gastrointestinal and skin toxicity were observed with greater phosphorylation or quantities of EGFR, ERK, and AKT in tumor samples ( P ≤ .05). Gefitinib had limited clinical activity as monotherapy despite documented target inhibition. CONCLUSIONS The results from this study demonstrated that gefitinib inhibited the phosphorylation of EGFR in EOC tumor cells, providing proof of target in a clinical setting. Combinatorial therapy with molecular therapeutics against complementary targets may prove successful. Cancer 2007. Published 2007 by the American Cancer Society." @default.
• W2028662865 created "2016-06-24" @default.
• W2028662865 creator A5005621340 @default.
• W2028662865 creator A5021155879 @default.
• W2028662865 creator A5033625395 @default.
• W2028662865 creator A5034858590 @default.
• W2028662865 creator A5036138286 @default.
• W2028662865 creator A5037416583 @default.
• W2028662865 creator A5044239219 @default.
• W2028662865 creator A5050485639 @default.
• W2028662865 creator A5068012456 @default.
• W2028662865 creator A5081819701 @default.
• W2028662865 date "2007-03-01" @default.
• W2028662865 modified "2023-10-16" @default.
• W2028662865 title "A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer" @default.
• W2028662865 cites W14479526 @default.
• W2028662865 cites W1580361048 @default.
• W2028662865 cites W1900738452 @default.
• W2028662865 cites W1967330952 @default.
• W2028662865 cites W1976421760 @default.
• W2028662865 cites W1977332018 @default.
• W2028662865 cites W1989051196 @default.
• W2028662865 cites W2001276579 @default.
• W2028662865 cites W2005274511 @default.
• W2028662865 cites W2007314461 @default.
• W2028662865 cites W2010174111 @default.
• W2028662865 cites W2022039302 @default.
• W2028662865 cites W2028747133 @default.
• W2028662865 cites W2036093957 @default.
• W2028662865 cites W2043696829 @default.
• W2028662865 cites W2043911313 @default.
• W2028662865 cites W2049938167 @default.
• W2028662865 cites W2055654338 @default.
• W2028662865 cites W2057458801 @default.
• W2028662865 cites W2071807692 @default.
• W2028662865 cites W2080847394 @default.
• W2028662865 cites W2096972798 @default.
• W2028662865 cites W2105453387 @default.
• W2028662865 cites W2106538825 @default.
• W2028662865 cites W2106660927 @default.
• W2028662865 cites W2109847775 @default.
• W2028662865 cites W2110675408 @default.
• W2028662865 cites W2111732555 @default.
• W2028662865 cites W2120018526 @default.
• W2028662865 cites W2122932716 @default.
• W2028662865 cites W2126134338 @default.
• W2028662865 cites W2126314379 @default.
• W2028662865 cites W2135148499 @default.
• W2028662865 cites W2141149378 @default.
• W2028662865 cites W2145844571 @default.
• W2028662865 cites W2148011209 @default.
• W2028662865 cites W2151126163 @default.
• W2028662865 cites W2151266270 @default.
• W2028662865 cites W2161821474 @default.
• W2028662865 cites W2167368130 @default.
• W2028662865 cites W2170071316 @default.
• W2028662865 cites W2170783473 @default.
• W2028662865 cites W2395162484 @default.
• W2028662865 doi "https://doi.org/10.1002/cncr.22545" @default.
• W2028662865 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2778218" @default.
• W2028662865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17330838" @default.
• W2028662865 hasPublicationYear "2007" @default.
• W2028662865 type Work @default.
• W2028662865 sameAs 2028662865 @default.
• W2028662865 citedByCount "131" @default.
• W2028662865 countsByYear W20286628652012 @default.
• W2028662865 countsByYear W20286628652013 @default.
• W2028662865 countsByYear W20286628652014 @default.
• W2028662865 countsByYear W20286628652015 @default.
• W2028662865 countsByYear W20286628652016 @default.
• W2028662865 countsByYear W20286628652017 @default.
• W2028662865 countsByYear W20286628652018 @default.
• W2028662865 countsByYear W20286628652019 @default.
• W2028662865 countsByYear W20286628652020 @default.
• W2028662865 countsByYear W20286628652021 @default.
• W2028662865 countsByYear W20286628652023 @default.
• W2028662865 crossrefType "journal-article" @default.
• W2028662865 hasAuthorship W2028662865A5005621340 @default.
• W2028662865 hasAuthorship W2028662865A5021155879 @default.
• W2028662865 hasAuthorship W2028662865A5033625395 @default.
• W2028662865 hasAuthorship W2028662865A5034858590 @default.
• W2028662865 hasAuthorship W2028662865A5036138286 @default.
• W2028662865 hasAuthorship W2028662865A5037416583 @default.
• W2028662865 hasAuthorship W2028662865A5044239219 @default.
• W2028662865 hasAuthorship W2028662865A5050485639 @default.
• W2028662865 hasAuthorship W2028662865A5068012456 @default.
• W2028662865 hasAuthorship W2028662865A5081819701 @default.
• W2028662865 hasBestOaLocation W20286628651 @default.
• W2028662865 hasConcept C11960822 @default.
• W2028662865 hasConcept C121608353 @default.
• W2028662865 hasConcept C126322002 @default.
• W2028662865 hasConcept C143998085 @default.
• W2028662865 hasConcept C2779438470 @default.
• W2028662865 hasConcept C2780427987 @default.
• W2028662865 hasConcept C2780580887 @default.
• W2028662865 hasConcept C2781230642 @default.
• W2028662865 hasConcept C502942594 @default.
• W2028662865 hasConcept C55493867 @default.

• next